ALPS Medical Breakthroughs ETF SBIO

Morningstar Medalist Rating

Morningstar’s Analysis SBIO

Will SBIO outperform in the future?

Get our overall rating based on a fundamental assessment of the pillars below.

null Morningstar Automated Analysis

Morningstar Automated Analysis

Summary

ALPS Medical Breakthroughs ETF holds a quantitatively derived Neutral Morningstar Medalist Rating. The rating suggests the model does not express a clear expectation of outperformance or underperformance relative to peers over a full market cycle.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings SBIO

  • Current Portfolio Date
  • Equity Holdings—
  • Bond Holdings—
  • Other Holdings—
  • % Assets in Top 10 Holdings33.2
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

Oruka Therapeutics Inc

4.589M
Healthcare

CG Oncology Inc

4.338M
Healthcare

Veradermics Inc

3.567M
Healthcare

Dianthus Therapeutics Inc

3.376M
Healthcare

Edgewise Therapeutics Inc

3.276M
Healthcare

Travere Therapeutics Inc Ordinary Shares

3.136M
Healthcare

Definium Therapeutics Inc Ordinary Shares

2.835M
Healthcare

Relay Therapeutics Inc Ordinary Shares

2.615M
Healthcare

Xenon Pharmaceuticals Inc

2.585M
Healthcare

Amylyx Pharmaceuticals Inc

2.505M
Healthcare

Sponsor Center